Prime Medicine, Inc. (PRME)
$4.59
Market is closed - opens 7 PM, 19 Apr 2024
Insights on Prime Medicine, Inc.
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 110.5%
Performance
- $4.57$4.97$4.59
0.54%
Downside
Day's Volatility :8.15%
Upside
7.65%
- $4.59$17.20$4.59
0.0%
Downside
52 Weeks Volatility :73.31%
Upside
73.31%
Returns
| Period | Prime Medicine, Inc. | Index (Russel 2000) |
|---|---|---|
3 Months | -22.85% | 0.0% |
6 Months | -34.53% | 0.0% |
1 Year | -63.83% | -1.5% |
3 Years | -67.92% | -21.8% |
Highlights
Market Capitalization | 632.1M |
Book Value | $1.44 |
Earnings Per Share (EPS) | -2.18 |
Wall Street Target Price | 15.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -43.15% |
Return On Equity TTM | -88.19% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -86.7M |
EBITDA | -186.6M |
Diluted Eps TTM | -2.18 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.83 |
EPS Estimate Next Year | -1.68 |
EPS Estimate Current Quarter | -0.51 |
EPS Estimate Next Quarter | -0.51 |
Analyst Recommendation
Buy
84%Buy
15%Hold
0
0%Sell
Based on 13 Wall street analysts offering stock ratings for Prime Medicine, Inc.(by analysts ranked 0 to 5 stars)
Based on 13 analyst
- Current
- 1M Ago
- 3M Ago
Buy
11
10
9
Hold
2
2
3
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 237.69%
Current $4.59
Target $15.50
Technicals Summary
Sell
Neutral
Buy
Prime Medicine, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Prime Medicine, Inc. | -29.77% | -34.53% | -63.83% | -67.92% | -67.92% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Prime Medicine, Inc. | NA | NA | NA | -1.83 | -0.88 | -0.43 | NA | 1.44 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Prime Medicine, Inc. | Buy | $632.1M | -67.92% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Alphabet Inc
9.89%Vanguard Group Inc
3.38%FMR Inc
3.27%BlackRock Inc
3.15%Sumitomo Mitsui Trust Holdings Inc
2.93%Nikko Asset Management Americas Inc
2.93%
Company Information
Organization | Prime Medicine, Inc. |
Employees | 234 |
CEO | Dr. Keith Michael Gottesdiener Ph.D. |
Industry | Miscellaneous |
